Consistency Analysis of Programmed Death-Ligand 1 Expression between Primary and Metastatic Non-Small Cell Lung Cancer: A Retrospective Study

Luo, Luqiao; Luo, Xinlan; Chen, Wendan; Liang, Chunyan; Yao, Su; Huang, Weihong; Liu, Chao; Ge, Yan; Lin, Xingtao; Li, Zhi

doi:10.7150/jca.34793



International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

Global reach, higher impact

Full Text | PDF

J Cancer 2020; 11(4):974-982. doi:10.7150/jca.34793 This issue Cite

Research Paper

Consistency Analysis of Programmed Death-Ligand 1 Expression between Primary and Metastatic Non-Small Cell Lung Cancer: A Retrospective Study

Luqiao Luo^*, Xinlan Luo^*, Wendan Chen, Chunyan Liang, Su Yao, Weihong Huang, Chao Liu, Yan Ge, Xingtao Lin, Zhi Li^✉

Citation:

Luo L, Luo X, Chen W, Liang C, Yao S, Huang W, Liu C, Ge Y, Lin X, Li Z. Consistency Analysis of Programmed Death-Ligand 1 Expression between Primary and Metastatic Non-Small Cell Lung Cancer: A Retrospective Study. J Cancer 2020; 11(4):974-982. doi:10.7150/jca.34793. https://www.jcancer.org/v11p0974.htm

Other styles

Abstract

Background: Programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer (NSCLC) is considered as a predictive biomarker of anti-PD-1/PD-L1 cancer therapies. However, the correlation of PD-L1 expression status between the primary and paired metastatic NSCLC is still not clear. The current study aims to address this specific issue.

Materials and Methods: The PD-L1 expression of the primary and paired metastatic lesions from 110 patients with NSCLC was retrospectively evaluated by immunohistochemical assay using Anti-PD-L1 antibody, Clone 22C3. The results were assessed by the Tumor Proportion Score (TPS) using cutoff values of <1%, 1%-49% and ≥50%. Meanwhile, the Cohen's kappa coefficient (k) of agreement was calculated.

Results: An overall concordance rate of the PD-L1 expression between the primary and metastatic lesions was 61% (63/103) (k = 0.39, and P < 0.001). If using TPS considering 1% and 50% as a threshold, the inconsistent rate was 28/103 (27.2%) paired specimens (k = 0.46, and P < 0.001) and 14/103 (13.6%) paired specimens (k = 0.53, and P < 0.001), respectively. Moreover, the concordance of the PD-L1 expression between primary and metastatic tumor was also analyzed according to the clinical stages within the untreated group of patients. We observed that for patients with stage I-III NSCLC, the concordance rate of the PD-L1 expression between primary and metastatic lesions was 81.3% and 100% when using 1% and 50% as threshold, respectively. While in stage IV patients, the concordance rate of the PD-L1 expression between the primary and metastatic lesions drops to 71.4% and 85.7%, respectively.

Conclusion: The PD-L1 expression was dynamic as tumor developed, which was valuable in selecting the proper type of sample for accurately evaluating the prognosis of using pembrolizumab as first or second line treatment.

Keywords: Programmed death-ligand 1 (PD-L1), non-small cell lung cancer (NSCLC), primary cancer, metastatic cancer.

Citation styles

APA

Luo, L., Luo, X., Chen, W., Liang, C., Yao, S., Huang, W., Liu, C., Ge, Y., Lin, X., Li, Z. (2020). Consistency Analysis of Programmed Death-Ligand 1 Expression between Primary and Metastatic Non-Small Cell Lung Cancer: A Retrospective Study. Journal of Cancer, 11(4), 974-982. https://doi.org/10.7150/jca.34793.

ACS

Luo, L.; Luo, X.; Chen, W.; Liang, C.; Yao, S.; Huang, W.; Liu, C.; Ge, Y.; Lin, X.; Li, Z. Consistency Analysis of Programmed Death-Ligand 1 Expression between Primary and Metastatic Non-Small Cell Lung Cancer: A Retrospective Study. J. Cancer 2020, 11 (4), 974-982. DOI: 10.7150/jca.34793.

NLM

CSE

Luo L, Luo X, Chen W, Liang C, Yao S, Huang W, Liu C, Ge Y, Lin X, Li Z. 2020. Consistency Analysis of Programmed Death-Ligand 1 Expression between Primary and Metastatic Non-Small Cell Lung Cancer: A Retrospective Study. J Cancer. 11(4):974-982.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.